Article
In the interest of ensuring the highest levels of safety for both surgeon and patient, two microkeratome manufacturers are initiating voluntary corrective action for two of their devices.
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
How food choices may affect non-refractive visual impairment
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
RhyGaze secures Series A financing of $86 million to further novel gene therapy
Ashvattha Therapeutics secures $50M in financing to advance clinical trials